Aelis Farma Balance Sheet Health
Financial Health criteria checks 6/6
Aelis Farma has a total shareholder equity of €9.9M and total debt of €3.9M, which brings its debt-to-equity ratio to 39.4%. Its total assets and total liabilities are €20.5M and €10.5M respectively.
Key information
39.4%
Debt to equity ratio
€3.92m
Debt
| Interest coverage ratio | n/a |
| Cash | €12.59m |
| Equity | €9.94m |
| Total liabilities | €10.53m |
| Total assets | €20.47m |
Recent financial health updates
No updates
Recent updates
Aelis Farma SA (EPA:AELIS) Might Not Be As Mispriced As It Looks After Plunging 26%
Dec 13
Take Care Before Jumping Onto Aelis Farma SA (EPA:AELIS) Even Though It's 29% Cheaper
Oct 21Aelis Farma SA's (EPA:AELIS) 49% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Sep 06Some Confidence Is Lacking In Aelis Farma SA (EPA:AELIS) As Shares Slide 49%
Sep 06Financial Position Analysis
Short Term Liabilities: AELIS's short term assets (€18.8M) exceed its short term liabilities (€6.3M).
Long Term Liabilities: AELIS's short term assets (€18.8M) exceed its long term liabilities (€4.2M).
Debt to Equity History and Analysis
Debt Level: AELIS has more cash than its total debt.
Reducing Debt: AELIS's debt to equity ratio has reduced from 169.1% to 39.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AELIS has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: AELIS is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 21:04 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aelis Farma SA is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dylan van Haaften | Bryan Garnier & Co |
| David Seynnaeve | Degroof Petercam |
| Martial Descoutures | ODDO BHF Corporate & Markets |